Critical Limb Ischemia Market Growth Forecast With Analysis Of Industry Progress Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Critical Limb Ischemia Market Change Between 2026 And 2030?

The critical limb ischemia market has experienced robust expansion in recent years. Forecasts indicate it will expand from $3.89 billion in 2025 to $4.25 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. Historically, this expansion has stemmed from factors such as high prevalence of peripheral artery disease, increasing diabetes incidence, aging population growth, reliance on surgical revascularization, and delayed disease diagnosis.

The critical limb ischemia market is projected to experience substantial expansion in the coming years, reaching $6 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.0%. This expansion during the forecast period is primarily due to advancements in vascular devices, an increase in minimally invasive procedures, the proliferation of specialized vascular centers, heightened awareness regarding limb preservation, and enhanced access to diagnostic imaging. Key developments anticipated within this period involve the increasing adoption of endovascular revascularization, a greater reliance on drug-eluting devices, the evolution of limb salvage treatment methodologies, the broadening of multidisciplinary vascular care, and an emphasis on prompt diagnosis and intervention.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9859&type=smp

What Important Drivers Are Powering The Critical Limb Ischemia Market Growth?

The increasing investments in healthcare infrastructure are projected to stimulate the expansion of the critical limb ischemia treatment market moving forward. Healthcare infrastructure investment involves dedicating financial resources to the development, improvement, and maintenance of essential physical structures, facilities, and systems that support the provision of healthcare services. This investment plays a vital role in critical limb ischemia (CLI) treatment by ensuring the availability of necessary facilities, equipment, and resources for accurate diagnosis and effective treatment of the condition. For instance, in May 2023, a report published by the Office for National Statistics, a UK-based government department, revealed that between 2022 and 2023, healthcare spending in the UK grew by 5.6% compared to a growth of 0.9% in 2022. The UK healthcare expenditure totaled approximately $317.63 billion (£292 billion) in 2023. Therefore, the rising investments in healthcare infrastructure are fueling the growth of the critical limb ischemia treatment market.

How Are Different Segment Groups Identified Within The Critical Limb Ischemia Market?

The critical limb ischemia market covered in this report is segmented –

1) By Type: Devices, Drugs, Surgery

2) By Medication: Antihypertensive Agents, Antiplatelet Drugs, Antithrombotic Agents, Other Medications

3) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Devices: Angioplasty Balloons, Stents, Catheters, Atherectomy Devices, Implantable Devices

2) By Drugs: Antiplatelet Agents, Vasodilators, Anticoagulants, Thrombolytics, Growth Factors And Cytokines

3) By Surgery: Bypass Surgery, Endarterectomy, Amputation, Revascularization Procedures

Which Trends Are Contributing To Changes In The Critical Limb Ischemia Market?

Key players in the critical limb ischemia (CLI) treatment market are introducing technologically advanced solutions, such as dissolving stents, to enhance therapeutic results for patients afflicted with this severe form of peripheral artery disease. Dissolving stents, also known as bioresorbable stents, are designed to offer transient support to the affected artery, subsequently disappearing as the vessel recovers. For instance, in April 2024, the US-based medical device firm Abbott Laboratories secured approval from the Food and Drug Administration (FDA), a US-based federal agency, for its Esprit BTK Everolimus Eluting Resorbable Scaffold System. This dissolving stent is specifically developed for individuals suffering from chronic limb-threatening ischemia (CLTI) in arteries located below the knee. This marks the initial approval of a dissolving stent tailored for this specific condition within the United States. The stent is fabricated from materials similar to those used in dissolving sutures and is engineered to gradually disintegrate over approximately three years following its implantation. It dispenses the immunosuppressive drug everolimus, which assists in averting the re-narrowing of arteries and promotes vessel healing.

Which Firms Are Competing In The Critical Limb Ischemia Market?

Major companies operating in the critical limb ischemia market are Medtronic Plc, Boston Scientific Corporation, Abbott Laboratories, LimFlow SA, Micro Medical Solutions, Cardiovascular Systems Inc., Shanghai MicroPort Medical (Group) Co Ltd., B. Braun SE, Teva Pharmaceutical Industries Ltd., Cook Medical, Philips, BD, Penumbra Inc., Cardinal Health Inc., Teleflex Incorporated, AngioDynamics Inc., Endologix Inc., Terumo Corporation, MicroPort Scientific, Silk Road Medical, LeMaitre Vascular Inc., Merit Medical Systems Inc., Shockwave Medical, Avinger, Biomerics LLC, Intact Vascular Inc., Bluegrass Vascular Technologies, PQ Bypass, Rex Medical, Aortica Corporation

Access The Complete Critical Limb Ischemia Market Report:

https://www.thebusinessresearchcompany.com/report/critical-limb-ischemia-global-market-report

Which Region Is The Primary Market For The Critical Limb Ischemia Market?

North America was the largest region in the critical limb ischemia treatment market in 2025. The regions covered in the critical limb ischemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Critical Limb Ischemia Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=9859&type=smp

Browse Through More Reports Similar to the Global Critical Limb Ischemia Market 2026, By The Business Research Company

Crispr Gene Editing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Crispr And Cas Gene Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-and-cas-gene-global-market-report

Plant Breeding And Crispr Plants Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/plant-breeding-and-crispr-plants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795